Thiazole Functionalization of Thiosemicarbazone for Cu(II) Complexation: Moving toward Highly Efficient Anticancer Drugs with Promising Oral Bioavailability
Molecules · 2024
DOI: 10.3390/molecules29163832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Song-Yu Luo und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry, Chemical Engineering, and Materials Science, Soochow University, Suzhou 215123, China. Hauptthemen laut MEDLINE: Thiosemicarbazones, Antineoplastic Agents, Copper, Thiazoles. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SuZhou LongMab Biosciences., Ltd, SuZhou LongMab Biosciences Ltd..
Abstract (Originalsprache)
In this work, we report the synthesis of a new thiosemicarbazone-based drug of N′-(di(pyridin-2-yl)methylene)-4-(thiazol-2-yl)piperazine-1-carbothiohydrazide (HL) featuring a thiazole spectator for efficient coordination with Cu(II) to give [CuCl(L)]2 (1) and [Cu(NO3)(L)]2 (2). Both 1 and 2 exhibit dimeric structures ascribed to the presence of di-2-pyridylketone moieties that demonstrate dual functions of chelation and intermolecular bridging. HL, 1, and 2 are highly toxic against hepatocellular carcinoma cell lines Hep-G2, PLC/PRF/5, and HuH-7 with half maximal inhibitory concentration (IC50) values as low as 3.26 nmol/mL (HL), 2.18 nmol/mL (1), and 2.54 × 10−5 nmol/mL (2) for PLC/PRF/5. While the free ligand HL may elicit its anticancer effect via the sequestration of bio-relevant metal ions (i.e., Fe3+ and Cu2+), 1 and 2 are also capable of generating cytotoxic reactive oxygen species (ROS) to inhibit cancer cell proliferation. Our preliminary pharmacokinetic studies revealed that oral administration (per os, PO) of HL has a significantly longer half-life t1/2 of 21.61 ± 9.4 h, nearly doubled as compared with that of the intravenous (i.v.) administration of 11.88 ± 1.66 h, certifying HL as an effective chemotherapeutic drug via PO administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry, Chemical Engineering, and Materials Science, Soochow University, Suzhou 215123, China.
- Suzhou Degen Bio-Medical Co., Ltd., No. 1 Huayun Road, Suzhou Industrial Park, Suzhou 215000, China.
ORCID-Profile: Wen-Hua Zhang
Förderung
- SuZhou LongMab Biosciences., Ltd
- SuZhou LongMab Biosciences Ltd.
Zitieren
APA
Luo, S. Y., Zeng, C. M., Xu, P., Ning, Y., Dong, M. L., Zhang, W. H., & Yu, G. (2024). Thiazole Functionalization of Thiosemicarbazone for Cu(II) Complexation: Moving toward Highly Efficient Anticancer Drugs with Promising Oral Bioavailability. Molecules. https://doi.org/10.3390/molecules29163832
Vancouver
Luo SY, Zeng CM, Xu P, Ning Y, Dong ML, Zhang WH, et al. Thiazole Functionalization of Thiosemicarbazone for Cu(II) Complexation: Moving toward Highly Efficient Anticancer Drugs with Promising Oral Bioavailability. Molecules. 2024. doi:10.3390/molecules29163832
BibTeX
@article{Luo2024,
author = {Luo, Song-Yu and Zeng, Chun-Mei and Xu, Ping and Ning, Ye and Dong, Meng-Lin and Zhang, Wen-Hua and Yu, Guangliang},
title = {Thiazole Functionalization of Thiosemicarbazone for Cu(II) Complexation: Moving toward Highly Efficient Anticancer Drugs with Promising Oral Bioavailability},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29163832}
}
EUVIMED